End-of-life and euthanasia decision-making

WSAVA guideline

Key findings

• Three ethical questions: acceptable? when? what method? (Ch.4, p.53). Grounds: relief/prevention of suffering (physical or psychological) or inability to provide the Five Welfare Needs (p.53).
• Convenience euthanasia = euthanasia of a physically and psychologically healthy animal; a top dilemma — 2012 UK survey: 57% of vets face 1–2 ethical dilemmas/week, 34% face 3–5/week (Batchelor & McKeegan 2011; Ch.4, p.50).
• Acceptance gradient: easier when obviously physically suffering; less acceptable for future suffering, mental-health reasons, population control or owner convenience — yet future welfare may already be compromised (disease progression, unowned/shelter animals, relinquishment risk) (p.53). Decision aids: IFAW 2011, BVA 2016.
• QoL assessment as printed: animal QoL relies on proxy measures by owners/vets, so instruments must be reliable/valid; most tools are disease-specific with no well-validated general methods (Belshaw et al. 2015); validated owner-generated general tools: Canine Symptom Assessment Scale (PennCHART 2016), Pet Problem Severity Scale (Spitznagel et al. 2018) (Ch.2, p.22). Elicit whether QoL or duration of life matters more to the owner (Ch.4, p.51).
• Timing: guided by welfare/QoL assessment; delaying euthanasia prolongs suffering — poor welfare outcome (p.53).
• Condemned agents: MgSO4 and KCl "actually result in a painful death and are not considered humane" (ICAM Coalition 2011(a)/(b); AVMA 2013) (p.53).
• Proper methods: only humane methods; follow the AVMA Guidelines for the Euthanasia of Animals (Leary et al. 2013) and the WSAVA Pain Guidelines Humane Euthanasia Overview (2014); method depends on restraint/drug availability per country; maintain a written clinic euthanasia policy (models: OSU Protocol 2011, DVM360 2007) (Ch.3, p.35).
• Client communication: owner/family presence requires prior discussion of what to expect and best interests of all (Ch.3, p.41); ~80% of communication non-verbal; clients remember only 25–50% (Ch.5, p.61).

Drugs named in WSAVA’s own guideline text

As printed in WSAVA’s document, not this app’s own extracted data — see “Related drugs in this reference” below for that.

• **Magnesium sulphate (MgSO4)** (🐕/🐈)

  Euthanasia agent (used where pharmaceutical euthanasia limited)

• **Potassium chloride (KCl)** (🐕/🐈)

  Euthanasia agent (as above)

Recommendations

• Maintain a written euthanasia policy in every clinic (Ch.3, p.35)

  Expert consensus (AWC)

• Use only humane methods; never MgSO4 or KCl (Ch.3 p.35; Ch.4 p.53)

  Expert consensus (AWC)

• Defer technique to AVMA + WSAVA Pain Guidelines (Ch.4, p.53)

  Expert consensus (AWC)

• Time by welfare state + QoL assessment; avoid delay (Ch.4, p.53)

  Expert consensus (AWC)

• Use validated QoL instruments (CSAS, PPSS); elicit QoL-vs-duration preference (Ch.2 p.22; Ch.4 p.51)

  Expert consensus (AWC)

• Discuss owner/family presence beforehand (Ch.3, p.41)

  Expert consensus (AWC)

• Recognise convenience euthanasia as a dilemma; use IFAW/BVA aids (Ch.4, p.50, p.53)

  Expert consensus (AWC)

• Know local legislation; FVE/AVMA/OIE hold vets ethically responsible for welfare (Ch.4, p.50–51)

  Expert consensus (AWC)

• Train communication for euthanasia discussions and grief (Ch.5, p.61)

  Expert consensus (AWC)

Related drugs in this reference (1)

The quoted line under each drug is its own already-extracted indication text that matched this condition — the reason it’s listed, not a paraphrase. Open a drug for its full species/route breakdown, calculator, and complete adverse-effect list.

Showing 1 of 1 linked drug record. Open a record for species, route and source details.

• PENTOBARBITAL SODIUM

  “For use in dogs for humane, painless, and rapid euthanasia.”

  Adverse-effect notes: For inquiries or to report suspected adverse drug experiences, please contact Parnell at 1-800-887-2763 or visit www.parnell.com. For additi… · To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Covetrus® North Ame…